Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA.
Baker S, et al. Among authors: liu m.
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):849-855. doi: 10.1016/j.ijrobp.2022.08.026. Epub 2022 Oct 24.
Int J Radiat Oncol Biol Phys. 2022.
PMID: 36302495
Clinical Trial.